|Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study|
S Blach, S Zeuzem, M Manns, I Altraif, AS Duberg, DH Muljono, I Waked, ...
The lancet Gastroenterology & hepatology 2 (3), 161-176, 2017
|Epidemiology and natural history of HCV infection|
B Hajarizadeh, J Grebely, GJ Dore
Nature reviews Gastroenterology & hepatology 10 (9), 553, 2013
|Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review|
L Degenhardt, A Peacock, S Colledge, J Leung, J Grebely, P Vickerman, ...
The Lancet Global Health 5 (12), e1192-e1207, 2017
|Hepatitis C virus treatment for prevention among people who inject drugs: modeling treatment scale‐up in the age of direct‐acting antivirals|
NK Martin, P Vickerman, J Grebely, M Hellard, SJ Hutchinson, VD Lima, ...
Hepatology 58 (5), 1598-1609, 2013
|Restrictions for Medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States|
S Barua, R Greenwald, J Grebely, GJ Dore, T Swan, LE Taylor
Annals of internal medicine 163 (3), 215-223, 2015
|The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection|
J Grebely, K Page, R Sacks‐Davis, MS van der Loeff, TM Rice, J Bruneau, ...
Hepatology 59 (1), 109-120, 2014
|Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis|
EJ Aspinall, S Corson, JS Doyle, J Grebely, SJ Hutchinson, GJ Dore, ...
Clinical Infectious Diseases 57 (suppl_2), S80-S89, 2013
|Elbasvir–grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy: a randomized trial|
GJ Dore, F Altice, AH Litwin, O Dalgard, EJ Gane, O Shibolet, ...
Annals of internal medicine 165 (9), 625-634, 2016
|Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: a systematic review, meta-analyses, and meta-regression|
R Waziry, B Hajarizadeh, J Grebely, J Amin, M Law, M Danta, J George, ...
Journal of hepatology 67 (6), 1204-1212, 2017
|Global statistics on alcohol, tobacco and illicit drug use: 2017 status report|
A Peacock, J Leung, S Larney, S Colledge, M Hickman, J Rehm, ...
Addiction 113 (10), 1905-1926, 2018
|Potential role for Interleukin‐28B genotype in treatment decision‐making in recent hepatitis C virus infection|
J Grebely, K Petoumenos, M Hellard, GV Matthews, V Suppiah, ...
Hepatology 52 (4), 1216-1224, 2010
|Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review|
S Larney, A Peacock, J Leung, S Colledge, M Hickman, P Vickerman, ...
The Lancet Global Health 5 (12), e1208-e1220, 2017
|Barriers associated with the treatment of hepatitis C virus infection among illicit drug users|
J Grebely, KA Genoway, JD Raffa, G Dhadwal, T Rajan, G Showler, ...
Drug and alcohol dependence 93 (1-2), 141-147, 2008
|Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine|
J Grebely, M Prins, M Hellard, AL Cox, WO Osburn, G Lauer, K Page, ...
The Lancet infectious diseases 12 (5), 408-414, 2012
|Low uptake of treatment for hepatitis C virus infection in a large community‐based study of inner city residents|
J Grebely, JD Raffa, C Lai, M Krajden, T Kerr, B Fischer, MW Tyndall
Journal of viral hepatitis 16 (5), 352-358, 2009
|What is killing people with hepatitis C virus infection?|
J Grebely, GJ Dore
Seminars in liver disease 31 (04), 331-339, 2011
|Hepatitis C virus reinfection in injection drug users|
J Grebely, B Conway, JD Raffa, C Lai, M Krajden, MW Tyndall
Hepatology 44 (5), 1139-1145, 2006
|Effective treatment of injecting drug users with recently acquired hepatitis C virus infection|
GJ Dore, M Hellard, GV Matthews, J Grebely, PS Haber, K Petoumenos, ...
Gastroenterology 138 (1), 123-135. e2, 2010
|Prioritization of HCV treatment in the direct-acting antiviral era: an economic evaluation|
NK Martin, P Vickerman, GJ Dore, J Grebely, A Miners, J Cairns, ...
Journal of hepatology 65 (1), 17-25, 2016
|Breaking down the barriers to hepatitis C virus (HCV) treatment among individuals with HCV/HIV coinfection: action required at the system, provider, and patient levels|
J Grebely, M Oser, LE Taylor, GJ Dore
The Journal of infectious diseases 207 (suppl_1), S19-S25, 2013